Amneal Pharmaceuticals price to free cash flow AMRX

Market value divided by free cash flow over the last twelve months, since 2019.

Today, Oct 23, 2026: 50.9×
7-year median: 9.1×
Against its 7-year history: 99th; percentile: 0 is its lowest day, 100 its highest
7-year range: 3.1× to 51.7×
Peer median: 46.0×

Amneal Pharmaceuticals' price to free cash flow is 50.9× as of Oct 23, 2026.

That is above its 7-year median of 9.1×, higher than on 99% of days in the last 7 years.

Over that time it ranged from 3.1× in Jul 2021 to 51.7× in May 2019.

The median for 10 large drugmakers of a similar size is 46.0×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	50.9×	13.8×	50.9×
2025	15.4×	8.9×	15.4×
2024	9.1×	5.5×	14.9×
2023	13.1×	5.9×	32.1×
2022	6.1×	5.3×	9.9×
2021	6.4×	3.1×	9.1×
2020	7.2×	3.9×	12.1×
2019	5.4×	3.3×	51.7×

Against its peers

Companies in Drug Manufacturers - General nearest Amneal Pharmaceuticals' size, closest first, today.

Company	Price to free cash flow
AMRXAmneal Pharmaceuticals	50.9×
LGNDLigand Pharmaceuticals	46.0×
KNSAKiniksa Pharmaceuticals International	32.7×
ALKSAlkermes plc.	33.0×
TGTXTG Therapeutics	477×
PTGXProtagonist Therapeutics	68.6×
CORTCorcept Therapeutics	86.8×
INDVIndivior Pharmaceuticals	n/m
ARQTArcutis Biotherapeutics	100×
BMRNBiomarin Pharmaceutical	14.7×
LQDALiquidia	25.3×
Peer median	46.0×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Amneal Pharmaceuticals

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.